Evaluation of the Diagnostic and Prognostic Potential, and Correlation with the Tumor Immune Microenvironment of a Six-miRNA Signature Associated with Platinum Sensitivity in Patients with Early-Stage Non-Small-Cell Lung Cancer
Abstract
Simple Summary Patients with non-small-cell lung cancer can respond differently to platinum-based chemotherapy, highlighting the need for reliable biomarkers that can help predict disease outcomes and support treatment decisions. In this study, we evaluated a panel of six small RNA molecules, called microRNAs, in tumor tissue and blood plasma from patients with surgically treated NSCLC who received platinum-based chemotherapy. The six-microRNA signature showed the ability to distinguish tumor from normal lung tissue and was associated with relapse-free survival. The microRNAs were also detectable in plasma, supporting their potential use as minimally invasive blood-based biomarkers. In addition, associations between specific microRNAs and immune-related markers within the tumor were identified, suggesting a possible link between the signature and the tumor immune environment. These findings support further investigation of this six-microRNA signature as a potential tool for patient stratification and outcome prediction in NSCLC.